Skip to main navigation Skip to search Skip to main content

Antiviral Inhibition of the HIV-1 capsid protein

  • Chun Tang
  • , Erin Loeliger
  • , Isaac Kinde
  • , Samson Kyere
  • , Keith Mayo
  • , Eric Barklis
  • , Yongnian Sun
  • , Mingjun Huang
  • , Michael F. Summers

Research output: Contribution to journal › Article › peer-review

Abstract

During the assembly stage of the human immunodeficiency virus (HIV) replication cycle, several thousand copies of the viral Gag polyprotein associate at the cell membrane and bud to form an immature, non-infectious virion. Gag is subsequently cleaved by the protease, which liberates the capsid proteins for assembly into the polyprotein shell of the central core particle (or capsid) of the mature virus. Viral infectivity is critically dependent on capsid formation and stability, making the capsid protein a potentially attractive antiviral target. We have identified compounds that bind to an apical site on the N-terminal domain of the HIV-1 capsid protein and inhibit capsid assembly in vitro. One compound, N-(3-chloro-4-methylphenyl)-N′-{2-[({5-[(dimethylamino)-methyl]-2- furyl}-methyl)-sulfanyl]ethyl}urea) (CAP-1), is well tolerated in cell cultures, enabling in vivo antiviral and mechanistic studies. CAP-1 inhibits HIV-1 infectivity in a dose-dependent manner, but does not interfere with viral entry, reverse transcription, integration, proteolytic processing, or virus production, indicating a novel antiviral mechanism. Significantly, virus particles generated in the presence of CAP-1 exhibit heterogeneous sizes and abnormal core morphologies, consistent with inhibited CA-CA interactions during virus assembly and maturation. These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS.

Original languageEnglish (US)
Pages (from-to)1013-1020
Number of pages8
JournalJournal of molecular biology
Volume327
Issue number5
DOIs
StatePublished - Apr 11 2003

Funding

This work was supported by NIH grant AI30917 (M.F.S.). I.K. is a Meyerhoff Undergraduate Scholar supported by HHMI Biological Sciences Initiative and NIH MARC funding, and E.L. is supported by a UMBC Presidential Undergraduate Scholarship. We thank David King (HHMI, U.C. Berkeley) for mass spectral measurements.

FundersFunder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health
Howard Hughes Medical Institute
National Institute of Allergy and Infectious DiseasesR01AI030917
University of Maryland Baltimore County

    Keywords

    • Antiviral inhibitors
    • Capsid assembly
    • HIV-1
    • Nuclear magnetic resonance

    ASJC Scopus subject areas

    • Biophysics
    • Structural Biology
    • Molecular Biology

    Fingerprint

    Dive into the research topics of 'Antiviral Inhibition of the HIV-1 capsid protein'. Together they form a unique fingerprint.

    Cite this